Loading...
XKRX
237690
Market cap1.08bUSD
May 02, Last price  
78,900.00KRW
1D
-0.13%
1Q
-9.10%
Jan 2017
75.92%
IPO
79.32%
Name

ST Pharm Co Ltd

Chart & Performance

D1W1MN
P/E
42.75
P/S
5.42
EPS
1,845.51
Div Yield, %
—
Shrs. gr., 5y
-1.20%
Rev. gr., 5y
24.03%
Revenues
273.75b
-3.94%
138,052,135,210200,361,532,900202,800,435,36297,738,455,80593,256,824,542124,108,663,975165,641,947,051249,321,677,973284,991,652,400273,751,342,840
Net income
34.71b
+77.27%
25,188,825,08061,425,867,57244,996,926,435-9,267,935,047-18,528,696,163-12,147,164,4473,312,124,53018,000,015,28019,581,189,74834,711,730,610
CFO
109.45b
+8,329.82%
35,821,583,86049,589,524,93255,593,624,79512,012,442,144-28,949,923,284-20,701,040,1587,648,753,9537,456,124,8071,298,383,430109,451,358,160
Dividend
Dec 27, 2023500 KRW/sh

Profile

ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. In addition, the company offers generic APIs for anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppressant, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medicines, as well as MRI contrast agents. Further, it provides 2nd battery, electronic materials, and polymer catalysts. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is based in Seoul, South Korea.
URL
https://www.stpharm.co.kr/
IPO date
Jun 23, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
273,751,343
-3.94%
284,991,652
14.31%
249,321,678
50.52%
Cost of revenue
210,772,045
218,988,478
200,391,422
Unusual Expense (Income)
NOPBT
62,979,298
66,003,174
48,930,256
NOPBT Margin
23.01%
23.16%
19.63%
Operating Taxes
10,282,745
5,830,842
1,721,312
Tax Rate
16.33%
8.83%
3.52%
NOPAT
52,696,553
60,172,332
47,208,944
Net income
34,711,731
77.27%
19,581,190
8.78%
18,000,015
443.46%
Dividends
(9,404,388)
(9,404,388)
(9,404,388)
Dividend yield
0.60%
0.74%
0.57%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
73,375,061
30,250,033
115,333,066
Long-term debt
47,436,831
165,013,048
19,187,686
Deferred revenue
22,206,386
23,731,252
24,584,342
Other long-term liabilities
18,630,099
19,222,230
6,686,170
Net debt
46,152,901
94,437,677
72,828,052
Cash flow
Cash from operating activities
109,451,358
1,298,383
7,456,125
CAPEX
(82,805,749)
(43,244,230)
(60,663,455)
Cash from investing activities
(86,542,775)
(82,388,093)
(7,078,965)
Cash from financing activities
(10,953,895)
82,732,434
11,737,715
FCF
50,726,176
(21,565,756)
(59,283,006)
Balance
Cash
120,923,834
90,097,156
50,201,066
Long term investments
(46,264,843)
10,728,248
11,491,634
Excess cash
60,971,424
86,575,822
49,226,616
Stockholders' equity
169,372,689
160,965,937
156,726,812
Invested Capital
600,998,124
533,009,609
455,154,850
ROIC
9.29%
12.18%
11.89%
ROCE
9.51%
10.61%
9.58%
EV
Common stock shares outstanding
17,563
18,809
18,809
Price
88,900.00
31.12%
67,800.00
-22.60%
87,600.00
-37.07%
Market cap
1,561,312,384
22.43%
1,275,234,945
-22.60%
1,647,648,690
-36.57%
EV
1,607,324,100
1,372,028,682
1,723,947,901
EBITDA
88,561,725
89,029,873
66,530,513
EV/EBITDA
18.15
15.41
25.91
Interest
7,738,485
6,105,605
2,867,836
Interest/NOPBT
12.29%
9.25%
5.86%